Use of the expression of specific genes for the prognosis of patients with triple negative breast cancer

Abstract

The present invention relates to the use of the value of the expression of at least one gene selected from the group comprising: GBP 1 gene, HLF gene, CXCL13 gene and SULT1E1 gene, for the estimation of prognosis of distant relapse-free survival or overall survival of a patient with triple negative breast cancer (TNBC) having received a neoadjuvant chemotherapy (NACT).

The invention claimed is: 
     
       1. A method of treating a patient with triple negative breast cancer (TNBC) comprising:
 measuring mRNA quantity resulting from expression from genes GBP1, HLF, CXCL13 and SULT1E1 in a sample taken from a biopsy from a tumor of the patient before neoadjuvant chemotherapy; 
 determining a genomic predictor score of more than or equal to 0.51 based on the measured mRNA quantity according to formula:
   Genomic predictor score=0.288*GBP1 expression+0.392*CXCL13 expression-1.027*HLF expression−1.726*SULT1E1 expression; and
 
 
 treating the patient with a neoadjuvant chemotherapy (NACT). 
 
     
     
       2. The method according to  claim 1 , wherein the method allowing measurement of mRNA quantity is selected from the group consisting of micro array, PCR, RT-PCR, and Affymetrix gene array. 
     
     
       3. The method according to  claim 1 , wherein the four genes corresponding to GBP1 gene, HLF gene, CXCL13 gene and SULT1E1 gene are respectively represented by the nucleotide sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4.